Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050531 · ClinicalTrials.gov registry record · Phase 3
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 94
- Enrollment target
NCT00050531: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00050531 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 94 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050531, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 94 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating CML in chronic phase than therapy with imatinib mesylate alone.
Interventions
- DRUG Gleevec
- DRUG Peg-alpha interferon (Peg-Intron)
- DRUG Sargramostim (GM-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2003-04 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050531
The ClinicalTrials.gov registry entry for NCT00050531 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 94 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gleevec is the first listed.
NCT00050531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050531 about?
NCT00050531 is a clinical study titled "High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)". The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating CML in chronic phase than therapy with imatinib mesylate alone.
What is the current status of trial NCT00050531?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 94 participants. The study started on 2003-04. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00050531?
The interventions under investigation include: Gleevec (DRUG), Peg-alpha interferon (Peg-Intron) (DRUG), Sargramostim (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT00050531?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.